Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Reaffirmed as Sell by HC Wainwright

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “sell” rating reiterated by equities researchers at HC Wainwright in a research note issued to investors on Monday, Marketbeat Ratings reports. They presently have a $5.00 price target on the biotechnology company’s stock. HC Wainwright’s target price points to a potential downside of 71.11% from the company’s current price.

A number of other research firms have also commented on SRPT. JPMorgan Chase & Co. reduced their price target on shares of Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating for the company in a research report on Wednesday, September 30th. Wall Street Zen downgraded Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Piper Sandler dropped their price objective on Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating for the company in a research note on Thursday, July 9th. William Blair raised Sarepta Therapeutics to a “hold” rating in a research note on Wednesday, September 23rd. Finally, Weiss Ratings cut Sarepta Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 24th. Seven analysts have rated the stock with a Buy rating, seven have issued a Hold rating and seven have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Sarepta Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $22.71.

Sarepta Therapeutics Trading Down 1.0%

Shares of Sarepta Therapeutics stock opened at $17.31 on Monday. Sarepta Therapeutics has a 12-month low of $14.68 and a 12-month high of $25.32. The company has a market cap of $1.83 billion, a price-to-earnings ratio of -5.97, a PEG ratio of 0.27 and a beta of 0.38. The company has a current ratio of 4.42, a quick ratio of 2.62 and a debt-to-equity ratio of 0.55. The company’s 50-day moving average price is $19.06 and its 200-day moving average price is $18.82.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.64 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $0.42. The company had revenue of $401.25 million during the quarter, compared to analyst estimates of $366.39 million. Sarepta Therapeutics had a negative net margin of 13.48% and a negative return on equity of 1.60%. Sarepta Therapeutics’s revenue was down 34.3% compared to the same quarter last year. During the same period last year, the business earned $2.02 earnings per share. On average, equities analysts expect that Sarepta Therapeutics will post 3.27 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sarepta Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of SRPT. PNC Financial Services Group Inc. increased its stake in shares of Sarepta Therapeutics by 7.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 8,751 shares of the biotechnology company’s stock worth $190,000 after purchasing an additional 636 shares in the last quarter. Public Employees Retirement System of Ohio raised its holdings in Sarepta Therapeutics by 3.1% in the 1st quarter. Public Employees Retirement System of Ohio now owns 28,787 shares of the biotechnology company’s stock worth $626,000 after purchasing an additional 875 shares during the period. Baird Financial Group Inc. lifted its position in Sarepta Therapeutics by 7.6% during the second quarter. Baird Financial Group Inc. now owns 12,805 shares of the biotechnology company’s stock valued at $230,000 after purchasing an additional 901 shares in the last quarter. Meeder Asset Management Inc. purchased a new position in Sarepta Therapeutics during the second quarter valued at $27,000. Finally, Rockefeller Capital Management L.P. grew its holdings in Sarepta Therapeutics by 98.3% during the fourth quarter. Rockefeller Capital Management L.P. now owns 4,104 shares of the biotechnology company’s stock valued at $88,000 after purchasing an additional 2,034 shares during the period. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc (NASDAQ: SRPT) is a biotechnology company focused on developing and commercializing precision genetic medicines for rare diseases. Its research programs include RNA-based therapies, gene therapy and other genetic medicine approaches designed to address the underlying causes of serious genetic disorders.

The company’s primary commercial focus has been Duchenne muscular dystrophy (DMD). Sarepta markets Exondys 51, Vyondys 53 and Amondys 45, exon-skipping therapies for certain patients with DMD mutations, as well as Elevidys, a gene therapy for eligible patients with Duchenne muscular dystrophy.